Release Date: 30-Aug-2023
Vabysmo, which was approved and launched in the market in 2022, is one of the important drugs produced by Roche that has been fueling the company’s growth and assisting it in maintaining its position as one of the world’s leading pharmaceutical companies. Vabysmo has received regulatory approval to treat neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME). Vabysmo’s sales have justified its market position as one of the best medicines available for treating various eye problems. Roche announced Vabysmo sales of CHF 957 Million (about US$ 1090.98 Million) in the first half of 2023, making it a blockbuster. This figure is much greater than Vabysmo’s full-year 2022 sales of CHF 591 million (US$ 673.74 million). Roche recently filed an application for Vabysmo’s approval for the treatment of retinal vein occlusion (RVO), which will boost its revenues in the future years.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028